This is a preview of subscription content, log in via an institution to check access.
Reference
Li S, et al. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis. Clinical Therapeutics : 27 Jun 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.05.015
Rights and permissions
About this article
Cite this article
Daratumumab + chemotherapy for newly diagnosed, transplant-ineligible multiple myeloma: survival benefits at acceptable cost. PharmacoEcon Outcomes News 883, 14 (2021). https://doi.org/10.1007/s40274-021-7885-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7885-7